All News

The number of urodynamic studies conducted by urologists applying for board certification or recertification more than doubled in less than a decade, with most of the procedures being performed in men with symptoms of urinary obstruction and in women with urinary incontinence.

Teva Pharmaceutical Industries Ltd. and Mylan Inc. have separately announced that they received FDA approval for generic versions of tamsulosin hydrochloride capsules, 0.4 mg, for the treatment of signs and symptoms of BPH.

A blood test for certain forms of PSA and measurement of DNA content in biopsy tissue accurately predict which men with potentially non-lethal prostate cancers may eventually need treatment, say urologists from Johns Hopkins University, Baltimore.

Gonadotropin-releasing hormone (GnRH) agonists have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several FDA studies.

This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes U.S. phase II bladder cancer trials that are currently recruiting participants. This list is current as of April 7, 2010.

The two biggest issues that come to mind in light of the current economic climate are how well you're communicating within the urology practice and how the economy might affect staff performance.

San Francisco has cuisine to satisfy any taste buds. From dim sum to gnocchi, use this guide to map out your dining tour of the city by the bay. Note: All phone numbers use the area code 415.

Although the request to revise the urodynamics codes was initiated by Medicare, the request was to change the CPT code descriptions to reflect the fact that the old 51772 and the old 51795 were billed in conjunction with code 51726 almost all the time.

Selenium and vitamin are E not promising, but both the Prostate Cancer Prevention Trial and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial showed a 20% to 25% reduction in the incidence of prostate cancer from two different 5-alpha-reductase inhibitors, finasteride (Proscar) and dutasteride (Avodart).